BioSpace News Archive

It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.

ObsEva SA announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation 68th Annual Meeting, being held virtually and in Boston July 6 -9, 2021.

Nicox SA, an international ophthalmology company, announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase as well as the required two-week follow up period.

On April 30th, SonoScape received the CE-marking, the product’s “Passport to Europe”, for its linear-array echoendoscope EG-UC5T. This further expands SonoScape’s endoscopic ultrasound (EUS) portfolio in the international market

Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to provide an update on three R&D programs: Fibromun, OncoFAP and ABBV-022.

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), announced positive Phase 1 clinical trial results at the 81st Scientific Sessions of the American Diabetes Association (ADA), June 25th – 29th.

HUTCHMED Limited will be announcing its interim results for the six months ended June 30, 2021 on Wednesday, July 28, 2021 at 12:00 noon British Summer Time ; 7:00 am Eastern Daylight Time ).

MISSISSAUGA, ON, July 2, 2021 /PRNewswire/ - Covalon Technologies Ltd., an advanced medical technologies company, announced the results of the matters voted upon at its Fiscal 2020 Annual and Special Meeting of Shareholders held June 30th, 2021.

Labcorp, a leading global life sciences company, will release its financial results for the second quarter of 2021 before the market opens on Thursday, July 29, 2021.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announced that second quarter of fiscal year 2021 financial results will be reported after the market closes on Monday, August 9th.